Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Surgery, Oral Devices Associated With Improvement In Sleep Breathing Disorder
Treatment with surgery or an oral appliance that adjusts the jaw is associated with improvements in obstructive sleep apnea, a condition caused by blocked upper airways in which patients periodically stop breathing during sleep, according to two reports in the May issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
generic viagra online
Brits Abroad Leave Depressed Friends At Home
New research reveals Brits prefer to rearrange or cancel their summer holiday than go with a friend who has mental illness. The British would prefer to go on their summer holiday with a friend who has a criminal record than go with a friend who has a mental health problem, a new survey as part of the Time to Change campaign [1] has found.
plastic surgery before after
News of the day
Surgeon General Nominee Backs Obama's Positions On Reproductive Health, White House Says
The Washington Post reports that Regina Benjamin -- President Obama"s nominee for U.S. surgeon general -- shares Obama"s position on reproductive health issues, a position that could put her "at odds" with the Catholic Church"s positions on reproductive rights, according to s familiar with her selection. White House spokesperson Reid Cherlin said, "Like [Obama], she believes that this is an issue where it is important to try and seek common ground and come together to try and reduce the number of unintended pregnancies." Cherlin added, "As a physician, she is deeply committed to the philosophy of putting her patients" needs first when it comes to providing care." The White House would not specifically comment on her views on abortion rights, and an HHS spokesperson says Benjamin is not permitted to speak publicly until she is confirmed. s close to Benjamin, who is Catholic, say that she does support abortion rights, the Post reports. However, several individuals who know Benjamin said her views would not affect her role as surgeon general. David Satcher -- a surgeon general in the Clinton administration who taught community health to Benjamin at the Morehouse School of Medicine -- said, "We all have our religions, but when you speak as the surgeon general to the American people, it"s not about your religion." He added, "I don"t see why the surgeon general has to get involved in a discussion about abortion." Jorge Alsip -- president of the Medical Association of the State of Alabama -- said abortion-related issues occasionally arose when he and Benjamin served on the Alabama State Committee on Public Health. Alsip, who is Catholic, said he does not know her position on the issue, adding, "You kind of have to park your personal beliefs at the door when they conflict with what your role is."Sister Carol Keehan, president and CEO of the Catholic Health Association, said, "This is not pivotal to the surgeon general"s job." She added, "From the perspective of being a practicing Catholic, you can certainly say that it matters. I think being willing to work to reduce (abortion) is a good thing."Robert Lawrence, a director at Johns Hopkins University"s Bloomberg School of Public Health and chair of the board of Physicians for Human Rights, served with Benjamin on the group"s board from 1996 until 2002. He said, "I would think that as surgeon general she would uphold the law of the land, and the law of the land guarantees women a choice for reproductive health." He added, "The charge of the surgeon general is to be the people"s doctor and ensure that all those health services guaranteed under federal law are available to the people" (Thompson, Washington Post, 7/19).
Public Health

Investigational Cancer Drug BSI-201 Showed Clinical Benefit In 62% Of Patients With Triple-Negative Metastatic Breast Cancer

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage. In this study, 116 women with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone receptors and without overexpression of HER2, were randomly assigned to receive GC in combination with the investigational agent BSI-201 or GC alone. Patients assigned to receive chemotherapy without BSI-201 were allowed to receive BSI-201 at the time of disease progression. The primary study endpoint was the rate of clinical benefit, defined as complete or partial response or stable disease of at least 6 months. Secondary study endpoints included progression-free survival, overall survival and safety. Approximately 62 percent of patients receiving BSI-201 in combination with GC showed clinical benefit, compared with 21 percent in the group receiving chemotherapy alone (p= 0.0002). Tumor response (complete or partial response) was observed in 48 percent of patients who received BSI-201 combined with chemotherapy, whereas patients receiving chemotherapy alone showed a response rate of 16 percent. Women who received BSI-201 had a median progression-free survival of 6.9 months and overall survival of 9.2 months compared with 3.3 and 5.7 months, respectively, for women who received chemotherapy alone. The hazard ratios for progression free survival and overall survival were 0.342 (pAbout ASCO ASCO is the world"s leading professional organization representing physicians who care for people with cancer. Approximately 30,000 cancer specialists from around the world are expected to gather at ASCO to discuss the latest advances in cancer care, treatment, prevention and survivorship. More than 4,000 abstracts have been accepted to the meeting, which will focus on the theme of "Personalizing Cancer Care", a practice focusing on caring for the individual - not just treating the disease - through the entire spectrum of care from prevention, diagnosis, and treatment to survivorship and end of life care. About BSI-201 Among other investigational PARP inhibitors in the industry, BSI-201 is the furthest along in clinical development in metastatic TNBC. BSI-201 is currently being evaluated for its potential to enhance the effect of chemotherapy-induced DNA damage. The clinical development of BSI-201 is supported by well documented safety profile based on studies of more than 200 patients. About TNBC When patients are diagnosed with breast cancer, their tumors are routinely tested for the presence of estrogen and progesterone receptors and for the over-expression of HER2. Commonly used breast cancer therapies target these receptors; for example, tamoxifen for estrogen receptor and trastuzumab (Herceptin(r)) for HER2. However, 15-20% of all breast cancers lack over-expression of all three proteins, thus giving rise to the term "triple- negative breast cancer" or "TNBC." TNBC can be an aggressive disease, with higher rates of metastases and poorer survival rates than other breast cancer subtypes. No treatment has been approved specifically for TNBC. About BiPar Sciences BiPar Sciences is a biopharmaceutical organization pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. In addition to BSI-201, the company also has two additional compounds in preclinical development. BiPar Sciences, located in Brisbane, California, is a fully-owned subsidiary of sanofi-aventis, Inc. About Sanofi Aventis Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). Forward Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis" management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis" annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements. Sanofi Aventis


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009